Objective: To assess the efficacy and safety of escitalopram in treating specific phobia. Method: The study was performed in an academic medical center. Adults meeting DSM-IV criteria for specific phobia were randomly assigned to 12 weeks of double-blind treatment with escitalopram or placebo. Efficacy measures included the Main Phobia Scale (MPS), the Marks Fear Questionnaire (FQ) and the Clinical Global Impressions of Improvement (CGI-I) scale. Data were collected between September 2002 and September 2004. Results: Of 13 subjects enrolled, 12 returned for at least one post-randomization visit and were included in the intent to treat sample. Response rates on the various subscales of the MPS and the FQ ranged from 20 to 80% for escitalopram, compared to 0—43% with placebo. Rates of response using the CGI-I scale were 60% for escitalopram and 29% for placebo, with a strong between treatment effect in favor of the drug at week 12 (effect-size = 1.13). Using the last observation carried forward, no statistically significant treatment differences were found. The drug was well tolerated. Conclusion: Treatment response was consistently greater for escitalopram than for placebo, with strong effects observed in favor of the drug. However, treatment differences on the primary outcome measures were not significant in this under-powered pilot study. Escitalopram may hold promise as a treatment for specific phobia and larger randomized controlled trials are needed.
Accurso V., Winnicki M., Shamsuzzaman A.S., Wenzel A., Johnson A.K., Somers V.K. (2001) Predisposition to vasovagal syncope in subjects with blood/injury phobia. Circulation104: 903—907
2.
Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H., di Girolamo G., Graaf R., Demyttenaere K., Gasquet I., Haro J.M., Katz S.J., Kessler R.C., Kovess V., Lepine J.P., Ormel J., Polidori G., Russo L.J., Vilagut G., Almansa J., Arbabzadeh-Bouchez S., Autonell J., Bernal M., Buist-Bouwman M.A., Codony M., Domingo-Salvany A., Ferrer M., Joo S.S., Martinez-Alonso M., Matschinger H., Mazzi F., Morgan Z., Morosini P., Palacin C., Romera B., Taub N., Vollenbergh W.A., ESEMeD/Mhedea2000Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand420(Suppl.): 21—27
3.
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Text Revision. American Psychiatric Association , Washington, DC
4.
Barlow J.H., Ellard D.R., Hainsworth J.M., Jones F.R., Fisher A. (2005) A review of self-management intervention for panic disorders, phobias and obsessive compulsive disorders. Acta Psychiatr Scand112: 272—285
5.
Benjamin J., Ben-Zion I.Z., Karbofsky E., Dannon P. (2000) Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl)149: 194—196
6.
Cohen S. (1988) Statistical power analysis for the behavioral sciences , 2nd edn. Lawrence Earlbaum Associates, Hillsdale, NJ
Curtis G.C., Magee W.J., Eaton W.W., Wittchen H.U., Kessler R.C. (1998) Specific fears and phobias. Epidemiology and classification . Br J Psychiatry173: 212—217
9.
Davidson J R T, Tupler L.A., Potts N L S (1994) Treatment of social phobia with benzodiazepines . J Clin Psychiatry55(Suppl. 6): 28—32
10.
DeJongh A., Van den Oord H.J., ten Broke E. (2002) Efficacy of eye movement desensitization and reprocessing in the treatment of specific phobias: four single case studies in dental phobias . J Clin Psychol58: 1453—1463
11.
Gelernter J., Page G.P., Stein M.B., Woods S.W. (2003) A chromosome 14 risk locus for simple phobia: results from a genomewide linkage scan. Mol Psychiatry8: 71—82
12.
Guy W. (1976) ECDEU assessment manual for psychopharmacology — Revised (DHEW Publ No ADM 76-338). US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, pp. 218—222
13.
Hamilton M. (1959) The assessment of anxiety states by rating. Br J Med Psychol32: 50—55
14.
Jorm A.F., Christensen H., Griffiths K.M., Parslow R.A., Rodgers B., Blewitt K.A. (2004) Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Austr181(Suppl. 7): S29—S46
15.
Kawakami N., Takeshima T., Ono Y., Uda H., Hata Y., Nakane Y., Nakane H., Iwata N., Furukawa T.A., Kikkawa T. (2005) Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary findings from the World Mental Health Japan survey 2002—2003. Psychiatry Clin Neurosci59: 441—452
16.
Kendler K.S., Myers J., Prescott C.A., Neale M.C. (2001) The genetic epidemiology of irrational fears and phobias in men. Arch Gen Psychiatry58: 257—265
17.
Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry62: 593—602
18.
Kessler R.C., McGonagle K.A., Zhao S.Z., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. (1994) Lifetime and 12-month prevalence of DSM-III-R Psychiatric Disorders in the United States. Arch Gen Psychiatry51: 8—19
19.
Koch E.I., Spates C.R., Himle J.A. (2004) Comparison of behavioral and cognitive-behavioral one-session exposure treatments for small animal phobias. Behav Res Ther42: 1483—1504
20.
Krasucki C., Howard R., Mann A. ( 1998) The relationship between anxiety disorders and age. Int J Geriatr Psychiatry13: 79—99
21.
Marks I.M., Mathews A.M. (1979) Brief standard self-rating for phobic patients . Behav Res Ther17: 263—267
22.
Medina-Mora M.E., Borges G., Lara C., Benjet C., Blanco J., Fleiz C., Villatoro J., Rojas E., Zambrano J. (2005) Prevalence, service use, and demographic correlates of 12-month DSM-IV psychiatric disorders in Mexico: results from the Mexican National Comorbidity Survey. Psychol Med35: 1773—1783
23.
Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther283: 1305—1322
24.
Pigott T.A. (2003) Anxiety disorders in women. Psychiatr Clin North Am26: 621—672, vi—vii
25.
Romeo E., Strohle A., Spalleta G., Di Michele F. (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry155: 910—913
26.
Sheehan D.V. (1986) The anxiety disease. Bantam Books, New York
27.
Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E. et al. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.):the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry59 (Suppl. 20): 22—33
28.
Shen Y.C., Zhang M.Y., Huang Y.Q., Liu Z.R., Cheng H., Tsang A., Lee S., Kessler R.C. (2006) Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China. Psychol Med36: 257—267
29.
Straube T., Glauer M., Dilger S., Mentzel H.J., Miltner W.H. (2006) Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage29: 125—135
30.
Waxman D. (1997) The management of phobic disorders using clomipramine (anafranil). J Int Med Res5 (Suppl. 1): 24—31
